Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 23:15:839-850.
doi: 10.2147/JAA.S360828. eCollection 2022.

Perspectives for the Use of Bacterial Lysates for the Treatment of Allergic Rhinitis: A Systematic Review

Kamil Janeczek  1 , Agnieszka Kaczyńska  1 , Andrzej Emeryk  1 , Cemal Cingi  2
Affiliations
Review

Perspectives for the Use of Bacterial Lysates for the Treatment of Allergic Rhinitis: A Systematic Review

Kamil Janeczek et al. J Asthma Allergy. .

Abstract

Bacterial lysates (BLs) are mixtures of bacterial antigens that have been used for many decades to minimize the risk of recurrent respiratory tract infections in both pediatric and adult populations. Research on the use of BLs is also conducted in allergology. Biomedical databases were searched for articles on the use of BLs in the treatment of allergic rhinitis (AR). After rejecting ineligible articles, six remaining reports were reviewed. Based on this review, it can be concluded that adding BL to standard therapy for seasonal or perennial AR reduces the severity of nasal symptoms and the need for antiallergic medications in both children and adults. Concurrently, these formulations have a high safety profile. An analysis of studies shows that the first effects of BLs therapy appear at the earliest 2-6 weeks after the start of treatment and persist at least 3 months after treatment.

Keywords: allergic rhinitis; bacterial lysate; immunostimulation; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare that are relevant to the content of this article. No funding was received to assist with the preparation of this manuscript.

Figures

Figure 1
Figure 1
The search strategies.
Figure 2
Figure 2
Summaries of the risk of bias in the RCT (A) and non-RCT (B) studies.
Figure 3
Figure 3
Graph of the risk of bias in the RCT studies.,
Figure 4
Figure 4
Possible pathways of PMBL action in AR.,,,
See this image and copyright information in PMC

References

    1. Meirlaen L, Levy EI, Vandenplas Y. Prevention and management with pro-, pre and synbiotics in children with asthma and allergic rhinitis: a narrative review. Nutrients. 2021;13(3):934. doi:10.3390/nu13030934 - DOI - PMC - PubMed
    1. Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743. doi:10.1016/S0140-6736(06)69283-0 - DOI - PubMed
    1. Cingi C, Bayar Muluk N, Scadding GK. Will every child have allergic rhinitis soon? Int J Pediatr Otorhinolaryngol. 2019;118:53–58. doi:10.1016/j.ijporl.2018.12.019 - DOI - PubMed
    1. Hallit S, Raherison C, Malaeb D, Hallit R, Kheir N, Salameh P. The AAA risk factors scale: a new model to screen for the risk of asthma, allergic rhinitis and atopic dermatitis in children. Med Princ Pract. 2018;27(5):472–480. doi:10.1159/000490704 - DOI - PMC - PubMed
    1. Small P, Keith PK, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):51. doi:10.1186/s13223-018-0280-7 - DOI - PMC - PubMed